Trial reportClinical optometry2026
Comparison of the Influence of Two Types of Silicone Hydrogel Daily Disposable Contact Lenses on Clinical Signs of Allergic Conjunctivitis Symptoms.
Trial report in Clinical optometry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Contact lens (CL) wear can exacerbate allergic conjunctivitis. This study compared the effects of narafilcon A and verofilcon A on clinical signs of allergic conjunctivitis in CL wearers. Our previous studies using the same crossover cohort examined subjective CL comfort and related symptoms and tear-film stability and surface wettability. In contrast, the present study specifically evaluated objective clinical signs of allergic conjunctivitis, which were not the primary outcomes of those previous studies. Methods: The study included 62 CL wearers, comprising 124 eyes, who experienced CL discomfort. Participants were randomized to a cross-over design, wearing narafilcon A and verofilcon A each for 2 weeks. Ten clinical signs associated with allergic conjunctivitis related to the palpebral conjunctiva, bulbar conjunctiva, corneal limbus, and cornea were scored on a 4-point scale (0-3) according to the Japanese guidelines for allergic conjunctival diseases (3rd edition). The total score was calculated by summing the scores of the 10 items (0-30, with lower scores indicating better outcomes). Results: No participants discontinued narafilcon A or verofilcon A due to intolerance during the study period. Compared to baseline, there was no significant worsening of the mean total allergic conjunctivitis score for either narafilcon A or verofilcon A. Furthermore, the mean total score was significantly lower for verofilcon A (1.8 ± 1.4) compared to narafilcon A (4.1 ± 3.0, p < 0.01). Conclusion: These findings suggest that verofilcon A may be associated with more favorable clinical signs of allergic conjunctivitis than narafilcon A in CL wearers with CL discomfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.